-
1
-
-
11144354339
-
Prevalence of age-related macular degeneration in the United States
-
Friedman DS, O’Colmain BJ, Muñoz B, et al; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564-572.
-
(2004)
Arch Ophthalmol
, vol.122
, Issue.4
, pp. 564-572
-
-
Friedman, D.S.1
O’Colmain, B.J.2
Muñoz, B.3
-
2
-
-
0031695623
-
Age-specific prevalence and causes of blindness and visual impairment in an older population: The Rotterdam study
-
Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam study. Arch Ophthalmol. 1998;116(5):653-658.
-
(1998)
Arch Ophthalmol
, vol.116
, Issue.5
, pp. 653-658
-
-
Klaver, C.C.1
Wolfs, R.C.2
Vingerling, J.R.3
Hofman, A.4
De Jong, P.T.5
-
3
-
-
0033796842
-
Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: The Blue Mountains Eye Study
-
Wang JJ, Foran S, Mitchell P. Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye Study. Clin Exp Ophthalmol. 2000;28(4):268-273.
-
(2000)
Clin Exp Ophthalmol
, vol.28
, Issue.4
, pp. 268-273
-
-
Wang, J.J.1
Foran, S.2
Mitchell, P.3
-
4
-
-
84892965801
-
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis
-
Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106-e116.
-
(2014)
Lancet Glob Health
, vol.2
, Issue.2
, pp. e106-e116
-
-
Wong, W.L.1
Su, X.2
Li, X.3
-
6
-
-
33751103471
-
Age-related macular degeneration - emerging pathogenetic and therapeutic concepts
-
Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration - emerging pathogenetic and therapeutic concepts. Ann Med. 2006;38(7):450-471.
-
(2006)
Ann Med
, vol.38
, Issue.7
, pp. 450-471
-
-
Gehrs, K.M.1
Erson, D.H.2
Johnson, L.V.3
Hageman, G.S.4
-
7
-
-
1942542429
-
Age-related macular degeneration is the leading cause of blindness
-
Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291(15):1900-1901.
-
(2004)
JAMA
, vol.291
, Issue.15
, pp. 1900-1901
-
-
Bressler, N.M.1
-
8
-
-
78449283380
-
Current and emerging therapies for the treatment of age-related macular degeneration
-
Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol. 2008;2(2):377-388.
-
(2008)
Clin Ophthalmol
, vol.2
, Issue.2
, pp. 377-388
-
-
Emerson, M.V.1
Lauer, A.K.2
-
9
-
-
85010867281
-
-
Accessed July 7
-
U.S. National Institutes of Health. Current studies: dry macular degeneration. Available from: https://clinicaltrials.gov/ct2/results?term=dry+macular+degeneration&Search=Search. Accessed July 7, 2016.
-
(2016)
Current Studies: Dry Macular Degeneration
-
-
-
10
-
-
84959537002
-
Regulation of signaling events involved in the pathophysiology of neovascular AMD
-
Wang H, Hartnett ME. Regulation of signaling events involved in the pathophysiology of neovascular AMD. Mol Vis. 2016;22:189-202.
-
(2016)
Mol Vis
, vol.22
, pp. 189-202
-
-
Wang, H.1
Hartnett, M.E.2
-
11
-
-
84973315122
-
MiR-126 regulation of angiogenesis in age-related macular degeneration in CNV mouse model
-
Wang L, Lee AY, Wigg JP, Peshavariya H, Liu P, Zhang H. miR-126 regulation of angiogenesis in age-related macular degeneration in CNV mouse model. Int J Mol Sci. 2016;17(6).
-
(2016)
Int J Mol Sci
, vol.17
, Issue.6
-
-
Wang, L.1
Lee, A.Y.2
Wigg, J.P.3
Peshavariya, H.4
Liu, P.5
Zhang, H.6
-
14
-
-
84881265267
-
-
Accessed July 18, 2016
-
US Food & Drug Administration. FDA approves Eylea for eye disorder in older people. 2011. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280601.htm. Accessed July 18, 2016.
-
(2011)
FDA Approves Eylea for Eye Disorder in Older People
-
-
-
15
-
-
84870723704
-
VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
-
Heier JS, Brown DM, Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
-
(2012)
Ophthalmology
, vol.119
, Issue.12
, pp. 2537-2548
-
-
Heier, J.S.1
Brown, D.M.2
Chong, V.3
-
16
-
-
84922391789
-
Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD
-
Ehlken C, Jungmann S, Böhringer D, Agostini HT, Junker B, Pielen A. Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye (Lond). 2014;28(5):538-545.
-
(2014)
Eye (Lond)
, vol.28
, Issue.5
, pp. 538-545
-
-
Ehlken, C.1
Jungmann, S.2
Böhringer, D.3
Agostini, H.T.4
Junker, B.5
Pielen, A.6
-
17
-
-
84455180610
-
Loss of reactivity in intravitreal anti-VEGF therapy: Tachyphylaxis or tolerance?
-
Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol. 2012;96(1):1-2.
-
(2012)
Br J Ophthalmol
, vol.96
, Issue.1
, pp. 1-2
-
-
Binder, S.1
-
18
-
-
85027938688
-
Treating the untreatable patient: Current options for the management of treatment-resistant neovascular age-related macular degeneration
-
Broadhead GK, Hong T, Chang AA. Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration. Acta Ophthalmol. 2014;92(8):713-723.
-
(2014)
Acta Ophthalmol
, vol.92
, Issue.8
, pp. 713-723
-
-
Broadhead, G.K.1
Hong, T.2
Chang, A.A.3
-
19
-
-
0041876133
-
Altman DG. Measuring inconsistency in meta-analyses.
-
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
-
(2003)
BMJ.
, vol.327
, Issue.7414
, pp. 557-560
-
-
Higgins, J.P.1
Thompson, S.G.2
Deeks, J.J.3
-
20
-
-
0031754739
-
The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions
-
Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377-384.
-
(1998)
J Epidemiol Community Health
, vol.52
, Issue.6
, pp. 377-384
-
-
Downs, S.H.1
Black, N.2
-
21
-
-
0037098199
-
Quantifying heterogeneity in a meta-analysis
-
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
-
(2002)
Stat Med
, vol.21
, Issue.11
, pp. 1539-1558
-
-
Higgins, J.P.1
Thompson, S.G.2
-
22
-
-
84929049456
-
Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration
-
Broadhead GK, Hong T, Zhu M, et al. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration. Retina. 2015;35(5):975-981.
-
(2015)
Retina
, vol.35
, Issue.5
, pp. 975-981
-
-
Broadhead, G.K.1
Hong, T.2
Zhu, M.3
-
23
-
-
84954373397
-
Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration: 12-month safety and efficacy outcomes
-
Chang AA, Broadhead GK, Hong T, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration: 12-month safety and efficacy outcomes. Ophthalmic Res. 2015;55(2):84-90.
-
(2015)
Ophthalmic Res
, vol.55
, Issue.2
, pp. 84-90
-
-
Chang, A.A.1
Broadhead, G.K.2
Hong, T.3
-
24
-
-
84891632111
-
Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration
-
Chang AA, Li H, Broadhead GK, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology. 2014;121(1):188-192.
-
(2014)
Ophthalmology
, vol.121
, Issue.1
, pp. 188-192
-
-
Chang, A.A.1
Li, H.2
Broadhead, G.K.3
-
25
-
-
84984914543
-
Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results
-
Aghdam KA, Pielen A, Framme C, Junker B. Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results. Eur J Ophthalmol. 2016;26(5):473-478.
-
(2016)
Eur J Ophthalmol
, vol.26
, Issue.5
, pp. 473-478
-
-
Aghdam, K.A.1
Pielen, A.2
Framme, C.3
Junker, B.4
-
26
-
-
84922020078
-
Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results
-
Grewal DS, Gill MK, Sarezky D, Lyon AT, Mirza RG. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye (Lond). 2014;28(7):895-899.
-
(2014)
Eye (Lond)
, vol.28
, Issue.7
, pp. 895-899
-
-
Grewal, D.S.1
Gill, M.K.2
Sarezky, D.3
Lyon, A.T.4
Mirza, R.G.5
-
27
-
-
84952918252
-
Conversion to aflibercept therapy versus continuing with ranibizumab therapy for neovascular age-related macular degeneration dependent on monthly ranibizumab treatment
-
Mantel I, Gianniou C, Dirani A. Conversion to aflibercept therapy versus continuing with ranibizumab therapy for neovascular age-related macular degeneration dependent on monthly ranibizumab treatment. Retina. 2016;36(1):53-58.
-
(2016)
Retina
, vol.36
, Issue.1
, pp. 53-58
-
-
Mantel, I.1
Gianniou, C.2
Dirani, A.3
-
28
-
-
84944339632
-
Intravitreal aflibercept for chorioidal neovascularization due to age-related macular degeneration unresponsive to ranibizumab therapy
-
Sarao V, Parravano M, Veritti D, Arias L, Varano M, Lanzetta P. Intravitreal aflibercept for chorioidal neovascularization due to age-related macular degeneration unresponsive to ranibizumab therapy. Retina. 2016;36(4):770-777.
-
(2016)
Retina
, vol.36
, Issue.4
, pp. 770-777
-
-
Sarao, V.1
Parravano, M.2
Veritti, D.3
Arias, L.4
Varano, M.5
Lanzetta, P.6
-
29
-
-
84902362487
-
Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)
-
Wykoff CC, Brown DM, Maldonado ME, Croft DE. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol. 2014;98(7):951-955.
-
(2014)
Br J Ophthalmol
, vol.98
, Issue.7
, pp. 951-955
-
-
Wykoff, C.C.1
Brown, D.M.2
Maldonado, M.E.3
Croft, D.E.4
-
30
-
-
84922675324
-
One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration
-
e2
-
Arcinue CA, Ma F, Barteselli G, Sharpsten L, Gomez ML, Freeman WR. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159(3):426436.e2.
-
(2015)
Am J Ophthalmol
, vol.159
, Issue.3
-
-
Arcinue, C.A.1
Ma, F.2
Barteselli, G.3
Sharpsten, L.4
Gomez, M.L.5
Freeman, W.R.6
-
31
-
-
85002498920
-
Fight Retinal Blindness! Project Investigators. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
-
Barthelmes D, Campain A, Nguyen P, et al; Fight Retinal Blindness! Project Investigators. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. Br J Ophthalmol. 2016;100(12):1640-1645.
-
(2016)
Br J Ophthalmol
, vol.100
, Issue.12
, pp. 1640-1645
-
-
Barthelmes, D.1
Campain, A.2
Nguyen, P.3
-
32
-
-
84922523441
-
Optical coherence tomographic and visual results at 6 months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (An American Ophthalmological Society thesis)
-
Chan CK, Jain A, Sadda S, Varshney N. Optical coherence tomographic and visual results at 6 months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2014;112:160-198.
-
(2014)
Trans am Ophthalmol Soc
, vol.112
, pp. 160-198
-
-
Chan, C.K.1
Jain, A.2
Sadda, S.3
Varshney, N.4
-
33
-
-
84966508433
-
Pigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: Time course and drug effects
-
de Massougnes S, Dirani A, Ambresin A, Decugis D, Marchionno L, Mantel I. Pigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: time course and drug effects. Retina. 2016;36(5):881-888.
-
(2016)
Retina
, vol.36
, Issue.5
, pp. 881-888
-
-
De Massougnes, S.1
Dirani, A.2
Ambresin, A.3
Decugis, D.4
Marchionno, L.5
Mantel, I.6
-
34
-
-
84911425292
-
Response to aflibercept in patients with persistent exudation despite prior treatment with bevacizumab or ranibizumab for age-related macular degeneration
-
Eadie JA, Gottlieb JL, Ip MS, et al. Response to aflibercept in patients with persistent exudation despite prior treatment with bevacizumab or ranibizumab for age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2014;45(5):394-397.
-
(2014)
Ophthalmic Surg Lasers Imaging Retina
, vol.45
, Issue.5
, pp. 394-397
-
-
Eadie, J.A.1
Gottlieb, J.L.2
Ip, M.S.3
-
35
-
-
84901762313
-
Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration
-
Gharbiya M, Iannetti L, Parisi F, De Vico U, Mungo ML, Marenco M. Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. BioMed Res Int. 2014;2014:273754.
-
(2014)
Biomed Res Int
, vol.2014
-
-
Gharbiya, M.1
Iannetti, L.2
Parisi, F.3
De Vico, U.4
Mungo, M.L.5
Marenco, M.6
-
36
-
-
84899952363
-
Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients
-
Hall LB, Zebardast N, Huang JJ, Adelman RA. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients. J Ocul Pharmacol Ther. 2014;30(4):346-352.
-
(2014)
J Ocul Pharmacol Ther
, vol.30
, Issue.4
, pp. 346-352
-
-
Hall, L.B.1
Zebardast, N.2
Huang, J.J.3
Adelman, R.A.4
-
37
-
-
84937041537
-
Quantification of change in pigment epithelial detachment volume and morphology after transition to intravitreal aflibercept in eyes with recalcitrant neovascular AMD: 18-month results
-
Kanesa-Thasan A, Grewal DS, Gill MK, Lyon AT, Mirza RG. Quantification of change in pigment epithelial detachment volume and morphology after transition to intravitreal aflibercept in eyes with recalcitrant neovascular AMD: 18-month results. Ophthalmic Surg Lasers Imaging Retina. 2015;46(6):638-641.
-
(2015)
Ophthalmic Surg Lasers Imaging Retina
, vol.46
, Issue.6
, pp. 638-641
-
-
Kanesa-Thasan, A.1
Grewal, D.S.2
Gill, M.K.3
Lyon, A.T.4
Mirza, R.G.5
-
38
-
-
84883740682
-
Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration
-
Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina. 2013;33(8):1605-1612.
-
(2013)
Retina
, vol.33
, Issue.8
, pp. 1605-1612
-
-
Kumar, N.1
Marsiglia, M.2
Mrejen, S.3
-
39
-
-
84952312163
-
Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
-
Narayan DS, Muecke J. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab. Indian J Ophthalmol. 2015;63(11):832-836.
-
(2015)
Indian J Ophthalmol
, vol.63
, Issue.11
, pp. 832-836
-
-
Narayan, D.S.1
Muecke, J.2
-
40
-
-
84918520233
-
Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD
-
Thorell MR, Nunes RP, Chen GW, et al. Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD. Ophthalmic Surg Lasers Imaging Retina. 2014;45(6):526-533.
-
(2014)
Ophthalmic Surg Lasers Imaging Retina
, vol.45
, Issue.6
, pp. 526-533
-
-
Thorell, M.R.1
Nunes, R.P.2
Chen, G.W.3
-
41
-
-
84880005310
-
Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab
-
Cho H, Shah CP, Weber M, Heier JS. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol. 2013;97(8):1032-1035.
-
(2013)
Br J Ophthalmol
, vol.97
, Issue.8
, pp. 1032-1035
-
-
Cho, H.1
Shah, C.P.2
Weber, M.3
Heier, J.S.4
-
42
-
-
84879235232
-
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
-
e1
-
Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013;156(1):1522.e1.
-
(2013)
Am J Ophthalmol
, vol.156
, Issue.1
-
-
Bakall, B.1
Folk, J.C.2
Boldt, H.C.3
-
43
-
-
84991085040
-
Predictors of outcome in patients with neovascular age-related macular degeneration switched from ranibizumab to 8-weekly aflibercept
-
Chatziralli I, Nicholson L, Vrizidou E, et al. Predictors of outcome in patients with neovascular age-related macular degeneration switched from ranibizumab to 8-weekly aflibercept. Ophthalmology. 2016;123(8):1762-1770.
-
(2016)
Ophthalmology
, vol.123
, Issue.8
, pp. 1762-1770
-
-
Chatziralli, I.1
Nicholson, L.2
Vrizidou, E.3
-
44
-
-
84930927133
-
Switch to aflibercept in the treatment of neovascular AMD: One-year results in clinical practice
-
Pinheiro-Costa J, Costa JM, Beato JN, et al. Switch to aflibercept in the treatment of neovascular AMD: one-year results in clinical practice. Ophthalmologica. 2015;233(3-4):155-161.
-
(2015)
Ophthalmologica
, vol.233
, Issue.3-4
, pp. 155-161
-
-
Pinheiro-Costa, J.1
Costa, J.M.2
Beato, J.N.3
-
45
-
-
84928491962
-
Functional and anatomic efficacy of a conversion to aflibercept in eyes with age-related macular degeneration after long-term ranibizumab treatment
-
Gerding H. Functional and anatomic efficacy of a conversion to aflibercept in eyes with age-related macular degeneration after long-term ranibizumab treatment. Klin Monbl Augenheilkd. 2015;232(4):560-563.
-
(2015)
Klin Monbl Augenheilkd
, vol.232
, Issue.4
, pp. 560-563
-
-
Gerding, H.1
-
46
-
-
84924218447
-
Quantitative OCT subanalysis of eyes with choroidal neovascularization switched from multiple injections of bevacizumab or ranibizumab to intravitreal aflibercept
-
Hariri A, Diniz B, Fou LV, Lam LA, Nittala MG, Sadda SR. Quantitative OCT subanalysis of eyes with choroidal neovascularization switched from multiple injections of bevacizumab or ranibizumab to intravitreal aflibercept. Ophthalmic Surg Lasers Imaging Retina. 2015;46(2):195-200.
-
(2015)
Ophthalmic Surg Lasers Imaging Retina
, vol.46
, Issue.2
, pp. 195-200
-
-
Hariri, A.1
Diniz, B.2
Fou, L.V.3
Lam, L.A.4
Nittala, M.G.5
Sadda, S.R.6
-
47
-
-
84930420653
-
Experience with aflibercept for the treatment of neovascular age-related macular degeneration
-
He L, Silva RA, Ayoub N, Moshfeghi DM, Leng T. Experience with aflibercept for the treatment of neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2015;46(5):542-549.
-
(2015)
Ophthalmic Surg Lasers Imaging Retina
, vol.46
, Issue.5
, pp. 542-549
-
-
He, L.1
Silva, R.A.2
Ayoub, N.3
Moshfeghi, D.M.4
Leng, T.5
-
48
-
-
84944173680
-
Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration
-
Major JC Jr, Wykoff CC, Croft DE, et al. Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration. Can J Ophthalmol. 2015;50(5):373-377.
-
(2015)
Can J Ophthalmol
, vol.50
, Issue.5
, pp. 373-377
-
-
Major, J.C.1
Wykoff, C.C.2
Croft, D.E.3
-
49
-
-
84982181964
-
Aflibercept in persistent neovascular AMD: Comparison of different treatment strategies in switching therapy
-
Ricci F, Parravano M, Regine F, et al. Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy. Eye (Lond). 2016;30(8):1077-1083.
-
(2016)
Eye (Lond)
, vol.30
, Issue.8
, pp. 1077-1083
-
-
Ricci, F.1
Parravano, M.2
Regine, F.3
-
50
-
-
84856134918
-
The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: The Lucentis Genotype Study (an American Ophthalmological Society thesis)
-
Francis PJ. The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2011;109:115-156.
-
(2011)
Trans am Ophthalmol Soc
, vol.109
, pp. 115-156
-
-
Francis, P.J.1
-
51
-
-
81555214460
-
Cytokines in neovascular age-related macular degeneration: Fundamentals of targeted combination therapy
-
de Oliveira Dias JR, Rodrigues EB, Maia M, Magalhães O Jr, Penha FM, Farah ME. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy. Br J Ophthalmol. 2011;95(12):1631-1637.
-
(2011)
Br J Ophthalmol
, vol.95
, Issue.12
, pp. 1631-1637
-
-
De Oliveira Dias, J.R.1
Rodrigues, E.B.2
Maia, M.3
Magalhães, O.4
Penha, F.M.5
Farah, M.E.6
-
52
-
-
84888610071
-
Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration
-
Krebs I, Glittenberg C, Ansari-Shahrezaei S, Hagen S, Steiner I, Binder S. Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol. 2013;97(11):1443-1446.
-
(2013)
Br J Ophthalmol
, vol.97
, Issue.11
, pp. 1443-1446
-
-
Krebs, I.1
Glittenberg, C.2
Ansari-Shahrezaei, S.3
Hagen, S.4
Steiner, I.5
Binder, S.6
-
53
-
-
40549112332
-
Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation
-
Moutray T, Alarbi M, Mahon G, Stevenson M, Chakravarthy U. Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation. Br J Ophthalmol. 2008;92(3):361-364.
-
(2008)
Br J Ophthalmol
, vol.92
, Issue.3
, pp. 361-364
-
-
Moutray, T.1
Alarbi, M.2
Mahon, G.3
Stevenson, M.4
Chakravarthy, U.5
-
54
-
-
84863320414
-
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results
-
Martin DF, Maguire MG, Fine SL, et al; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398.
-
(2012)
Ophthalmology
, vol.119
, Issue.7
, pp. 1388-1398
-
-
Martin, D.F.1
Maguire, M.G.2
Fine, S.L.3
-
55
-
-
84891634699
-
CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials
-
Grunwald JE, Daniel E, Huang J, et al; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121(1):150-161.
-
(2014)
Ophthalmology
, vol.121
, Issue.1
, pp. 150-161
-
-
Grunwald, J.E.1
Daniel, E.2
Huang, J.3
-
56
-
-
84983427934
-
Factors associated with poor response to aflibercept after switching from ranibizumab or bevacizumab in neovascular age-related macular degeneration
-
Cheng S, Leng T. Factors associated with poor response to aflibercept after switching from ranibizumab or bevacizumab in neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2016;47(5):458-465.
-
(2016)
Ophthalmic Surg Lasers Imaging Retina
, vol.47
, Issue.5
, pp. 458-465
-
-
Cheng, S.1
Leng, T.2
-
57
-
-
84973458175
-
Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: A comprehensive review
-
Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;10:1857-1867.
-
(2016)
Drug Des Devel Ther
, vol.10
, pp. 1857-1867
-
-
Yang, S.1
Zhao, J.2
Sun, X.3
-
58
-
-
68749090044
-
Cohort studies: Prospective versus retrospective
-
Euser AM, Zoccali C, Jager KJ, Dekker FW. Cohort studies: prospective versus retrospective. Nephron Clin Pract. 2009;113(3):c214-c217.
-
(2009)
Nephron Clin Pract
, vol.113
, Issue.3
, pp. c214-c217
-
-
Euser, A.M.1
Zoccali, C.2
Jager, K.J.3
Dekker, F.W.4
-
59
-
-
84881409196
-
Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial)
-
Menon G, Chandran M, Sivaprasad S, Chavan R, Narendran N, Yang Y. Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial). Eye (Lond). 2013;27(8):959-963.
-
(2013)
Eye (Lond)
, vol.27
, Issue.8
, pp. 959-963
-
-
Menon, G.1
Chandran, M.2
Sivaprasad, S.3
Chavan, R.4
Narendran, N.5
Yang, Y.6
-
60
-
-
84947996837
-
Scheduled versus Pro Re Nata Dosing in the VIEW trials
-
Richard G, Monés J, Wolf S, et al. Scheduled versus Pro Re Nata Dosing in the VIEW trials. Ophthalmology. 2015;122(12):2497-2503.
-
(2015)
Ophthalmology
, vol.122
, Issue.12
, pp. 2497-2503
-
-
Richard, G.1
Monés, J.2
Wolf, S.3
-
61
-
-
84930442296
-
Individualizing the intravitreal anti-VEGF dosing regimen for long-term management of neovascular AMD
-
Freund KB, Engelbert M, Fine HF. Individualizing the intravitreal anti-VEGF dosing regimen for long-term management of neovascular AMD. Ophthalmic Surg Lasers Imaging Retina. 2015;46(5):508-512.
-
(2015)
Ophthalmic Surg Lasers Imaging Retina
, vol.46
, Issue.5
, pp. 508-512
-
-
Freund, K.B.1
Engelbert, M.2
Fine, H.F.3
-
62
-
-
84891631034
-
Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the VIEW studies
-
Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193-201.
-
(2014)
Ophthalmology
, vol.121
, Issue.1
, pp. 193-201
-
-
Schmidt-Erfurth, U.1
Kaiser, P.K.2
Korobelnik, J.F.3
-
63
-
-
84455206370
-
Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation
-
Gasperini JL, Fawzi AA, Khondkaryan A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol. 2012;96(1):14-20.
-
(2012)
Br J Ophthalmol
, vol.96
, Issue.1
, pp. 14-20
-
-
Gasperini, J.L.1
Fawzi, A.A.2
Khondkaryan, A.3
-
64
-
-
67749106387
-
Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration
-
Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina. 2009;29(6):723-731.
-
(2009)
Retina
, vol.29
, Issue.6
, pp. 723-731
-
-
Forooghian, F.1
Cukras, C.2
Meyerle, C.B.3
Chew, E.Y.4
Wong, W.T.5
-
65
-
-
56549111386
-
Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?
-
Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 2008;115(12):2199-2205.
-
(2008)
Ophthalmology
, vol.115
, Issue.12
, pp. 2199-2205
-
-
Schaal, S.1
Kaplan, H.J.2
Tezel, T.H.3
-
66
-
-
84908551436
-
Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: A systematic review and meta-analysis of comparative studies
-
Wang W, He M, Zhang X. Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis of comparative studies. PLoS One. 2014;9(10):e110667.
-
(2014)
Plos One
, vol.9
, Issue.10
-
-
Wang, W.1
He, M.2
Zhang, X.3
-
67
-
-
84943351924
-
Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: A critical review and new possible approaches to move forward
-
Lazzeri S, Ripandelli G, Sartini MS, et al. Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward. Angiogenesis. 2015;18(4):397-432.
-
(2015)
Angiogenesis
, vol.18
, Issue.4
, pp. 397-432
-
-
Lazzeri, S.1
Ripandelli, G.2
Sartini, M.S.3
-
68
-
-
84962059540
-
A meta-analysis of studies evaluating visual and anatomical outcomes in patients with treatment resistant neovascular age-related macular degeneration following switching to treatment with aflibercept
-
Seguin-Greenstein S, Lightman S, Tomkins-Netzer O. A meta-analysis of studies evaluating visual and anatomical outcomes in patients with treatment resistant neovascular age-related macular degeneration following switching to treatment with aflibercept. J Ophthalmol. 2016;2016:4095852.
-
(2016)
J Ophthalmol
, vol.2016
-
-
Seguin-Greenstein, S.1
Lightman, S.2
Tomkins-Netzer, O.3
-
69
-
-
85013710337
-
Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration
-
Epub, Aug 30
-
Zhu M, Wijeyakumar W, Syed AR, et al. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. Epub 2016 Aug 30.
-
(2016)
Graefes Arch Clin Exp Ophthalmol
-
-
Zhu, M.1
Wijeyakumar, W.2
Syed, A.R.3
|